Tier 1 (verified): Billing — MBS Book July 2026 (items 23/36/44, 701–707, 2700–2701, 73840). NDSS — ndss.com.au May 2026. PBS standard benefit for listed insulins. Tier 2 (use clinical judgement): HbA1c initiation thresholds, starting dose, titration schedule. Drawn from:
· RACGP. Red Book 10th Ed., Aug 2025. racgp.org.au/red-book
· ADEA / Diabetes Australia. diabetesaustralia.com.au Disclaimer: Clinical thresholds must be individualised. This page is clinical reference only — not medical advice. Not affiliated with RACGP, ADEA, or the Department of Health.
📋 Source: RACGP, Management of type 2 diabetes: A handbook for general practice (updated May 2026) — “Initiating insulin” and Appendix 2: Guide to insulin initiation and titration (racgp.org.au). Dosing follows the handbook’s “start low, go slow” basal approach (10 units or 0.1–0.2 units/kg). Verified June 2026. Your doctor or healthcare provider knows your history and circumstances — always follow their personalised advice over general information.
RACGP Red Book Aug 2025Tier 2 — use clinical judgementBilling & NDSS = Tier 1
Clinical threshold and dosing sections (HbA1c triggers, starting dose, titration) are drawn from RACGP Red Book Aug 2025 and ADEA guidance — verified against current RACGP Red Book Aug 2025 and ADEA guidance; clinical use should be guided by your own judgement. Billing, NDSS, and PBS sections are Tier 1 (MBS Book July 2026 / ndss.com.au).
Pre-initiation checklist — clinical
Clinical triggers below are based on RACGP Red Book Aug 2025. Verify thresholds for your patient population.
0 of 7 completed
HbA1c above individualised target despite optimised oral therapyCommon trigger: ≥8.0% / 64 mmol/mol despite max tolerated oral agents — verify threshold for this patient
Driving requirements discussed and documentedAustroads AFTD 2022: patients on insulin must monitor BGL before driving. Commercial licence — DVA may apply. Document advice in notes.
Visual acuity and dexterity adequate for self-injectionIf significant impairment: consider involving carer, pen device vs vial, or referral to CDE for device assessment
GPCCMP reviewed or updated to reflect insulin initiationSignificant change in management — update plan goals and monitoring requirements. Items 2700/2701.
Pre-initiation checklist — administrative
0 of 5 completed
NDSS registration confirmedRequired for subsidised consumables (BGL strips, pen needles, lancets). Free — ndss.com.au or 1800 637 700. Source: NDSS.com.au
Insulin prescribed — PBS standard benefit (no authority required)All common insulins for T2DM are standard PBS benefit. Copay: $25.00 general, $7.70 concession.
Pen needles prescribed or arranged via NDSSPen needles are separate from insulin — prescribe separately or patient orders via NDSS if registered.
Sharps disposal arrangedUsed insulin pen needles require sharps disposal. Many councils offer free sharps programs. Pharmacy take-back varies by state.
Follow-up booked — 2 to 4 weeks for titration reviewCheck BGL diary, titration progress, injection site, side effects. Bill item 36 ($87.10) or 44 ($128.35) depending on duration. Source: MBS Book July 2026.
Starting dose recommendations are from RACGP Red Book Aug 2025 / ADEA guidance — use clinical judgement. Use clinical judgement. Always individualise for renal function, frailty, and hypoglycaemia risk.
Basal insulin starting dose estimator
Basal insulin once daily is the usual starting regimen for T2DM in general practice — simpler to initiate and associated with less hypoglycaemia than premix. Enter patient weight to calculate the suggested starting dose range.
Enter weight and hypoglycaemia risk above to calculate suggested starting dose.
Common basal insulins in Australian GP
Insulin glargine 100U/mL
Lantus / Basaglar
Once daily — any time, consistent timing. Standard first choice.
Insulin glargine 300U/mL
Toujeo
Once daily. Flatter profile — consider for higher hypo risk.
Insulin degludec
Tresiba
Once daily. Very long half-life — flexible dosing time. Less hypo.
Insulin detemir
Levemir
Once or twice daily. Weight-neutral in some studies.
All listed insulins are PBS standard benefit for T2DM — no authority required. General copay $25.00, concession $7.70.
Titration targets below are based on RACGP Red Book Aug 2025 / ADEA guidance — pending clinical review. Fasting BGL target of ≤7.0 mmol/L is commonly used for standard adult T2DM. Adjust for frailty, elderly (<8.5 mmol/L fasting), or hypoglycaemia risk.
Simple titration guide — 2-2-2 approach
Enter the current basal insulin dose and the patient's average fasting BGL over the last 3 days to get the next dose recommendation.
Current dose
units / day
Average fasting BGL (last 3 days)
mmol/L
Based on the "2–2–2 rule": increase by 2 units every 3 days if fasting BGL >7.0 mmol/L. Hold if 4.0–7.0 mmol/L. Review if <4.0 mmol/L. Source: RACGP Red Book Aug 2025 / ADEA guidance — Tier 2, pending clinical review. Adjust target for patient frailty and hypo risk.
Titration monitoring schedule
During titration phase
Fasting BGL daily — patient records in diary or app. Review at 2–4 weeks. HbA1c at 3 months (item 73840).
Once target reached and stable
Reduce fasting BGL monitoring frequency (discuss with patient). HbA1c 3-monthly until stable, then up to 4-monthly max (item 73840 — max 4/year).
If hypoglycaemia occurs
Reduce dose by 2–4 units. Review timing of injection and meal patterns. Consider switching to lower-hypo-risk insulin (Tresiba, Toujeo). Document in notes. Reinforce driving safety advice.
Consider referral to a CDE for patient education — CDEs have 30–60 min dedicated to injection technique, device use, and self-management. Most diabetes services can see patients within 1–2 weeks.
Topics to cover before the patient leaves
0 of 8 completed
Injection technique demonstrated and practised90-degree angle, 5–10 second hold, site rotation (abdomen / thigh / upper arm). Avoid lipohypertrophy areas.
Pen device use — loading, priming, dialling doseDemo with the actual pen the patient will take home. Show how to check the dose window. Priming: 2 units into air.
Storage instructions explainedUnopened: refrigerator (2–8°C). In use: room temperature, away from heat/sunlight. Most pens: 28–30 days once opened.
Hypoglycaemia — recognition and treatment explainedSymptoms: shaking, sweating, confusion, dizziness. Treatment: 15g fast carbs (glucose tablets / juice / jelly beans), wait 15 min, retest, repeat if still low. Always carry fast-acting carbs.
Driving safety — Austroads requirements explained and documentedMust test BGL <30 min before driving. Must not drive if BGL <5.0 mmol/L. Source: Austroads AFTD 2022. Must stop and treat if hypoglycaemia develops while driving. Commercial licence: stricter requirements.
Sick day management discussedDo not stop insulin when unwell — may need to increase. Monitor BGL more frequently. Know when to present to ED. If vomiting and unable to eat.
When to call — safety net providedPatient knows: who to call if BGL >15 mmol/L for >24h, persistent hypoglycaemia, unable to eat, extreme illness. Practice phone number given.
Starting insulin does not mean failure — addressed explicitlyMany patients have negative associations with insulin. Normalise it: "your body needs more support — this is a natural step in T2DM management."
NDSS — what this patient can now access
✓ Blood glucose test strips — subsidised through NDSS (quantity based on insulin regimen). Source: NDSS.com.au
✓ Pen needles and lancets — subsidised through NDSS
✓ Free NDSS diabetes education resources and support programs
✗ CGM — Type 2 diabetes is NOT eligible for NDSS CGM subsidy (regardless of insulin use). Source: NDSS.com.au, May 2026